Coronavirus vaccine

Patent metadata

Field	Value
Publication number	US-12208136-B2
Application number	US-202318186914-A
Country	US
Kind code	B2
Filing date	Mar 20, 2023
Priority date	Nov 29, 2021
Publication date	Jan 28, 2025
Grant date	Jan 28, 2025

Abstract

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

First claim

The invention claimed is:

1. A composition comprising: an RNA molecule having a nucleotide sequence that is at least 99% identical to that set forth in SEQ ID NO: 98;
wherein the RNA molecule comprises a 5′ cap; and
wherein the RNA molecule optionally comprises a modified uridine in place of one or more uridines.

2. The composition of claim 1 , wherein each of the uridines in the RNA molecule is replaced with a modified uridine.

3. The composition of claim 2 , wherein the modified uridine is N1-methyl-pseudouridine.

4. The composition of claim 1 , wherein the 5′ cap comprises m 2 7,3′-O Gppp(m 1 2′-O )ApG.

5. The composition of claim 1 , wherein the RNA molecule is encapsulated in a lipid nanoparticle (LNP).

6. A composition comprising an RNA molecule having a nucleotide sequence that is at least 99% identical to that set forth in SEQ ID NO: 98, wherein:
the RNA molecule comprises N1-methyl-pseudouridine in place of each uridine;
the RNA molecule comprises a 5′ cap that comprises m 2 7,3′-O Gppp(m 1 2′-O )ApG; and
the RNA molecule is encapsulated in a lipid nanoparticle (LNP).

7. The composition of claim 6 , comprising about 10 mM Tris buffer and about 10% sucrose.

8. The composition of claim 7 , wherein the composition is formulated as a multidose formulation in a vial.

9. A method of inducing an immune response, comprising administering to a subject the composition of claim 1 .

10. The method of claim 9 , wherein the RNA molecule comprises N1-methyl-pseudouridine in place of each uridine.

11. The method of claim 9 , wherein the 5′ cap comprises m 2 7,3′-O Gppp(m 1 2′-O )ApG.

12. The method of claim 9 , wherein the RNA molecule is encapsulated in an LNP.

13. The method of claim 9 , wherein the subject is 12 years or older, and the composition comprises 30 μg of the RNA molecule.

14. The method of claim 9 , wherein the subject is 5 years to less than 12 years old, and the composition comprises 10 μg of the RNA molecule.

15. The method of claim 9 , wherein the subject is 6 months to less than 5 years old, and the composition comprises 3 μg of the RNA molecule.

16. The method of claim 9 , wherein, prior to administering the composition of claim 1 , the subject is administered a first dose and a second dose of an RNA molecule comprising a sequence that is at least 99% identical to SEQ ID NO: 20;
wherein the second dose is administered about 21 days after the first dose; and
wherein the composition of claim 1 is administered at least about two months after the second dose.

17. The method of claim 9 , wherein the composition of claim 1 is administered in a volume of about 200 μL to 300 μL.

18. The method of claim 9 , wherein the subject was previously administered one or more doses of a SARS-CoV-2 vaccine.

19. The method of claim 18 , wherein the subject was previously administered a complete dosing regimen of a SARS-CoV-2 vaccine.

20. The method of claim 9 , wherein the composition is administered in conjunction with one or more vaccines targeting a different infectious agent.

21. The method of claim 20 , wherein the one or more vaccines targeting a different infectious agent comprise an influenza vaccine and/or an RSV vaccine.

22. A composition comprising at least one unit dose of a population of lipid nanoparticles (LNPs), wherein
each LNP in the population encapsulates at least one RNA molecule, wherein the at least one RNA molecule comprises:
(a) a nucleotide sequence that is at least 95% identical to SEQ ID NO: 98 and which encodes a polypeptide, wherein the polypeptide:
(i) has an amino acid sequence that is at least 95% identical to SEQ ID NO: 95;
(ii) comprises a proline substitution at one or both positions corresponding to residues 986 and 987 of SEQ ID NO: 1; and
(iii) comprises at least 10 of the following mutations as compared to SEQ ID NO: 1: T19I, Δ24-26, A27S, V83A, G142D, Δ144, H146Q, Q183E, V213E, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, and Q954H;

(b) N1-methyl-pseudouridine in place of each uridine; and
(c) a 5′ cap that comprises m 2 7,3′-O Gppp(m 1 2′-O )ApG.

23. The composition of claim 22 , comprising about 10 mM Tris buffer and about 10% sucrose.

24. The composition of claim 22 , wherein the unit dose comprises the RNA molecule in an amount of about 3 μg to about 30 μg.

25. The composition of claim 1 , wherein the SARS-CoV-2 S protein comprises a proline mutation at one or both positions corresponding to residues 986 and 987 of SEQ ID NO: 1.

26. The composition of claim 25 , wherein the SARS-CoV-2 S protein comprises at least 10 of the following mutations as compared to SEQ ID NO: 1: T19I, Δ24-26, A27S, V83A, G142D, Δ144, H146Q, Q183E, V213E, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, and Q954H.

27. The composition of claim 1 , wherein:
(a) the 5′-cap comprises m 2 7,3′-O Gppp(m 1 2′O )ApG;
(b) the RNA molecule comprises a 5′-UTR that comprises a modified human alpha-globin 5′-UTR;
(c) the RNA molecule comprises a 3′-UTR that comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA; and
(d) the RNA molecule comprises a poly(A) sequence comprising at least 100 A nucleotides.

28. The composition of claim 22 , wherein the RNA molecule comprises each of the following:
(a) a 5′-UTR that comprises a modified human alpha-globin 5′-UTR;
(b) a 3′-UTR that comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA; and
(c) a poly(A) sequence that comprises at least 100 A nucleotides.

Assignees

• BioNTech SE

Inventors

• Muik Alexander
• Swanson Kena Anne
• Yang Qi
• Cai Hui
• Sahin Ugur
• Modjarrad Kayvon

Classifications

• C12N2770/20071

  Demonstrated in vivo effect · CPC title

• C12N2770/20043

  viral genome or elements thereof as genetic vector · CPC title

• C12N2770/20034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2770/20022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2760/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title